Pharma News
15 Feb 2026 to 21 Feb 2026
Feb 21, 2026
MDC requests Biological E to make a decision regarding the exemption of Pneubevax 14 from DPCO pricing regulations.
The Multidisciplinary Committee of Experts (MDC) has invited Biological E to discuss its request for exemption of the 14-valent Pneumococcal Conjugate Vaccine, Pneubevax 14, from pricing regulations. The decision follows ongoing clarifications regarding its eligibility under the Drugs Prices Control Order (DPCO), 2013. Pneubevax 14 protects against 14 serotypes of Streptococcus pneumoniae and received WHO pre-qualification in November 2025.
Feb 21, 2026
Violations of Chapter IV of the Drugs and Cosmetics Act Can Only Be Heard by a Sessions Court, Not ...
The Supreme Court ruled that offences under Chapter IV of the Drugs and Cosmetics Act, 1940, concerning the manufacture and sale of drugs, must be tried exclusively by a Sessions Court, not a Magistrate. This decision emphasizes the seriousness of drug-related offences in India.
Feb 21, 2026
Over ₹1 Crore in Cash and Counterfeit Medications Confiscated in Significant Operation, DrugsControl Media Services
The Ayush Ministry, in collaboration with state authorities, conducted a major raid on an illegal Ayurvedic drug factory in Dehradun, seizing over Rs 1 crore in cash and counterfeit medicines. This operation highlights ongoing efforts to combat the production of fake pharmaceuticals in the region.
Feb 21, 2026
Abuse, trafficking, and breakdowns in supply chains drive the illegal trade of diverted pharmaceuticals.
A scandal involving codeine-based cough syrups in India reveals significant issues in the pharmaceutical supply chain, marked by misuse, smuggling, and regulatory failures. The situation highlights the urgent need for reforms to address the illicit trade in diverted medicines.
Feb 21, 2026
Is it a good time to invest in Bristol Myers Squibb after a 25% decline? | The Motley Fool
Bristol Myers Squibb (BMY) faces a significant patent cliff, with sales of key drugs Eliquis and Opdivo expected to decline after losing U.S. patent protection between 2027 and 2029. Despite this, the company’s growth portfolio, including the promising antipsychotic Cobenfy, could offset losses. Analysts suggest buying the dip, as the stock offers a 4.2% dividend yield.
Feb 21, 2026
Bristol Myers Squibb Confronts Patent Expiration Issues | Intellectia.AI
Guggenheim has raised its price target on Bristol Myers to $72 from $62, maintaining a Buy rating. The firm increased the success odds for iber/mezi to 90% from 33% and for milvexian in SSP to 90% from 75%, encouraging investors to buy shares ahead of significant Phase 3 catalysts.
Feb 21, 2026
Cellectar Biosciences Enhances Its Intellectual Property Portfolio in Anticipation of Important Regulatory Developments
Cellectar Biosciences has secured key patents in Europe and China for its lead drug, iopofosine I 131, enhancing its intellectual property as it prepares for a 2026 submission to the EMA for Waldenström's macroglobulinemia. The company also obtained patents for its pipeline asset CLR 125 and specialized dosing regimens, aiming for a potential commercial launch in early 2027.
Feb 21, 2026
Incyte's Aspirations in Europe Get Significant Regulatory Support - Ad-hoc-news.de
Incyte's immunotherapy drug, Zynyz, has received a positive recommendation from the EMA's CHMP for treating anal cancer, following successful Phase 3 trial results. This approval could enhance Incyte's European market presence as it seeks to offset upcoming patent expirations on existing products. The European Commission will review the recommendation for final authorization.
Feb 21, 2026
Is it a good time to invest in Bristol Myers Squibb after a 25% decline? - The Globe and Mail
Bristol Myers Squibb faces a significant patent cliff, with key drugs Eliquis and Opdivo losing U.S. patent protection between 2027 and 2029, potentially impacting $24.4 billion in sales. However, the company’s new antipsychotic drug, Cobenfy, could generate $3.4 billion annually by 2030 if approved. Analysts suggest buying the stock, currently undervalued, for potential long-term gains.
Feb 21, 2026
The global pharmaceutical industry faces a challenge: transitioning from quantity to quality | The Indian Express
India's pharmaceutical industry, producing 60% of the world's medicines, has significantly impacted global health, particularly through Cipla's antiretrovirals and Lupin's Rifampicin. The industry's success stems from supportive policies like India's Patents Act and the US's Hatch-Waxman Act. To reach a $350 billion export target by 2047, India must focus on value, innovation, and overcoming challenges in research and trade.
Feb 20, 2026
Maharashtra government requests ₹26.5 crore for a comprehensive drug monitoring system in response to efforts against counterfeit medications.
The Maharashtra government has requested ₹26.5 crore from the Central government to implement a state-wide "Track and Trace" system. This initiative, proposed by the Maharashtra Food and Drug Administration (FDA), aims to combat the increasing prevalence of counterfeit and spurious medicines in the state.
Feb 20, 2026
Corcept Experiences Legal Setback in Korlym Patent Case - The Globe and Mail
Corcept Therapeutics (CORT) announced that the U.S. Court of Appeals ruled in favor of Teva Pharmaceuticals, allowing its generic version of Korlym to proceed without infringing on Corcept's patents. CEO Joseph K. Belanoff expressed disappointment and plans to defend their intellectual property. The ruling raises competitive concerns for Corcept's flagship therapy for Cushing’s syndrome.
Feb 20, 2026
Pfizer Adjusts to a New Stage of Growth | Intellectia.AI
Wall Street analysts have mixed views on Pfizer Inc. (PFE), with 5 Buy and 11 Hold ratings. Barclays analyst Emily Field initiated coverage with an Underweight rating and a $25 price target, citing challenges due to loss of exclusivity. Daiwa's Narumi Nakagiri downgraded Pfizer from Outperform to Neutral with a $27 target.
Feb 20, 2026
Is Pfizer the Sole Pharmaceutical Stock I'd Consider Holding During a Market Downturn?
Pfizer is navigating a transition as demand for its coronavirus vaccine declines and it faces patent expirations on older blockbusters like Eliquis and Ibrance. The company is focusing on growth through acquisitions, including Seagen for oncology and Metsera for weight loss drugs. Pfizer reported over $10 billion in revenue from new products last year, positioning itself for future growth.
Feb 20, 2026
Will Immunology Medications Keep Boosting AbbVie's Revenue in 2026? - TradingView
AbbVie (ABBV) reported strong Q4 and full-year 2025 results, driven by immunology drugs Rinvoq and Skyrizi, which generated combined revenues of $26 billion, reflecting over 40% growth. AbbVie anticipates continued growth, projecting sales of Skyrizi and Rinvoq to exceed $31 billion in 2026. Despite competition from Johnson & Johnson (JNJ) and Eli Lilly (LLY), AbbVie remains optimistic about its market position.
Feb 20, 2026
Do obesity medications lead to serious complications? Insights from scientific research - Nature
The UK and Brazil have issued warnings about a potential link between GLP-1 drugs, used for obesity and diabetes, and acute pancreatitis, following reports of 19 deaths in the UK and six in Brazil. While the risk is noted in drug information leaflets, experts emphasize the need for further studies to clarify the association.
Feb 20, 2026
MDC suggests that nafithromycin, the first antibiotic developed locally, should be excluded from the DPCO regulations.
The Multidisciplinary Committee of Experts has recommended granting Wockhardt Ltd an exemption for its nafithromycin tablets, the first indigenous antibiotic in India, from pricing norms under the Drugs Prices Control Order. Nafithromycin, effective against drug-resistant bacteria, was launched in November 2024 and is expected to significantly improve treatment outcomes for Community-Acquired Bacterial Pneumonia.
Feb 20, 2026
Merck or Bristol Myers: Which Pharmaceutical Stock Will Be the Superior Choice in 2026? - Finviz
Merck & Co. (MRK) and Bristol Myers Squibb (BMY) are leading pharmaceutical companies with strong oncology portfolios. Merck's Keytruda drives significant revenue, while BMY's Opdivo and other drugs bolster its growth. Despite challenges, BMY is seen as a more attractive investment due to its favorable outlook and valuation, while MRK faces headwinds from generic competition and declining sales of key products.
Feb 20, 2026
Kirkland-based pharmacy startup employs unlicensed staff to manage GLP-1 drugs ... - KING 5 News
Whistleblowers have revealed that Aequita, a pharmacy owned by Mochi Health, employed unlicensed workers to handle GLP-1 weight-loss drugs like Ozempic and Mounjaro, raising serious safety concerns. The Washington State Department of Health is investigating the facility after reports of contamination and unsafe practices, including using substandard vials and improper packaging methods.
Feb 20, 2026
CDSCO Requires Revisions to Doxycycline and Carbimazole Prescribing Information to ...
The Central Drugs Standard Control Organization (CDSCO) has mandated updates to the prescribing information for Doxycycline and Carbimazole to enhance patient safety. This initiative aims to improve drug safety and increase patient awareness regarding these medications.
Feb 20, 2026
FTA commitments do not prevent major pharmaceutical companies from leaving - Business News | The Financial Express
Novartis AG's exit from its Indian subsidiary highlights Big Pharma's ongoing disinvestment trend in India, despite hopes that new trade agreements would boost interest. The company has shifted focus to innovative drugs while facing challenges from strict patent laws and competition from local firms. Analysts suggest that improving domestic standards are reshaping the pharmaceutical landscape in India.
Feb 19, 2026
Takeda Files Patent Lawsuit Aiming to Prevent Qilu from Producing a Generic Version of Livtencity - Bloomberg Law
Takeda Pharmaceutical Co. has filed a federal lawsuit against Qilu Pharmaceutical (Hainan) Co., claiming that its proposed generic version of Livtencity, containing the active ingredient maribavir, infringes six of its patents. The lawsuit was filed in the US District Court for the District of New Jersey, highlighting the ongoing legal battle over the treatment for serious viral infections in transplant patients.
Feb 19, 2026
Pay-for-Delay Arrangements in Turkey: Balancing Patent Rights and Antitrust Regulations - Mondaq
The Turkish Competition Authority (TCA) is scrutinizing "pay-for-delay" agreements in the pharmaceutical sector, which may hinder generic drug market entry. While no formal decisions have condemned such arrangements, TCA's approach aligns with EU law, emphasizing that agreements delaying competition could violate competition laws. Companies must ensure transparency and legitimate justifications in their settlements to avoid scrutiny.
Feb 19, 2026
Corcept Offers Update on Legal Battle with Teva Pharmaceuticals - Business Wire
Corcept Therapeutics announced that the U.S. Court of Appeals ruled in favor of Teva Pharmaceuticals, stating that its generic version of Korlym® does not infringe on Corcept's patents related to treating Cushing’s syndrome. Corcept's CEO expressed disappointment and plans to pursue judicial review of the decision. Korlym® is the first FDA-approved treatment for endogenous hypercortisolism.
Feb 19, 2026
Eli Lilly shares decline despite positive psoriasis results for Zepbound and Taltz; investors are looking ahead to the company's next moves.
Eli Lilly shares fell 1.8% despite positive late-stage trial results for its obesity drug Zepbound combined with psoriasis treatment Taltz. The combination therapy showed improved outcomes, with 27.1% achieving total skin clearance and weight loss. Lilly also plans to expand manufacturing in India and has secured rights to develop CSL's clazakizumab. Investors await an FDA ruling on orforglipron in April.
Feb 19, 2026
Patient groups express concerns about rising medication costs | Cyprus Mail
Cyprus' Federation of Patient Associations (Osak) is urging dialogue over revised drug categories that have led to increased costs for patients, particularly affecting the elderly. Complaints have surged as patients face higher contributions despite unchanged drug prices. Osak is in discussions with the health insurance organization (HIO) and calls for pharmaceutical companies to address these issues.
Feb 19, 2026
Analysis of the Patent Landscape for Cancer and Antibody Conjugates - GlobeNewswire
A new report titled "Cancer & Antibody Conjugates Patent Landscape Analysis 2025" has been released by ResearchAndMarkets.com, detailing over 3,700 patent families related to antibody-drug conjugates (ADCs) and radioimmunoconjugates. The report highlights key players like Pfizer, Roche, and AbbVie, and analyzes trends, IP positions, and emerging companies, particularly from China, in the rapidly evolving ADC market.
Feb 19, 2026
Corcept Issues Update Regarding Patent Litigation with Teva Pharmaceuticals – Company Statement
Corcept Therapeutics announced that the U.S. Court of Appeals ruled in favor of Teva Pharmaceuticals, stating that its generic version of Korlym® does not infringe on Corcept's patents related to Cushing’s syndrome treatment. Corcept's CEO, Joseph K. Belanoff, expressed disappointment and indicated plans to pursue judicial review of the decision.
Feb 19, 2026
Moonage Media Analysis: Clearmind's MEAI and GLP-1 - Could They Be the Future of ...
Clearmind Medicine (Nasdaq: CMND) is advancing its non-hallucinogenic neuroplastogen, MEAI, as a novel obesity treatment. Unlike GLP-1 drugs, MEAI targets the brain to promote cognitive flexibility and metabolic benefits, potentially reducing body weight by 20% while preserving muscle mass. The company is also pursuing new patents and collaborations to enhance MEAI's delivery and efficacy in weight management.
Feb 19, 2026
Pfizer Aims for Sustainable Growth in Oncology Despite Competitive Challenges - Finviz
Pfizer (PFE) reported an 8% growth in oncology revenues for 2025, driven by drugs like Xtandi and Padcev, despite declines in Ibrance sales. The FDA approved Padcev + Keytruda for muscle-invasive bladder cancer, marking a potential new standard of care. Pfizer's oncology biosimilars generated $1.3 billion in sales, and the company plans to expand its oncology pipeline significantly by 2030.
Feb 19, 2026
Disregard Ozempic: This Leading Obesity Medication Company Is Securing the Largest Share of the GLP-1 Market Boom.
Eli Lilly has overtaken Novo Nordisk in the GLP-1 drug market, capturing 60% share with its weight loss drug Zepbound and diabetes treatment Mounjaro, generating over $11 billion in revenue. Novo's Ozempic, while still popular, has seen its market share decline to 39%. Lilly's success is attributed to effective manufacturing and superior weight loss results in clinical studies.
Feb 19, 2026
US GAO: March-in rights offer limited relief for prescription drug costs | BioWorld
The US Government Accountability Office (GAO) reports that "march-ins" under the Bayh-Dole Act are not an effective solution for addressing high prescription drug prices. This comes amid ongoing demands from watchdog groups and lawmakers to consider drug pricing as a factor in government patent interventions, highlighting concerns over taxpayer-funded research contributions to drug development.
Feb 19, 2026
Biodexa Secures License for Phase 1 Drug Candidate from Otsuka Targeting Rare Stomach Cancer
Biodexa Pharmaceuticals has licensed MTX240, a Phase 1 ready drug candidate from Otsuka Pharmaceutical, aimed at treating gastrointestinal stromal tumors (GIST). MTX240's unique mechanism may offer benefits for TKI-resistant patients, addressing a significant unmet need in the $1.3 billion GIST market. Biodexa plans to initiate a Phase 1b/2a study by year-end to validate MTX240's efficacy.
Feb 19, 2026
Novo anticipates having an alternative to Ozempic available once the patent expires, according to Berlingske.
Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their patents expire in Europe in 2031 and the US in 2032. Chief Scientific Officer Martin Holst Lange stated that some drug candidates in clinical trials could be submitted for approval by 2030. More details will be shared at a capital markets day in London in September.
Feb 19, 2026
Novo Nordisk confronts increasing competition from generic brands - MedWatch
Pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's semaglutide, with Dr. Reddy planning a Wegovy copy at half the price in India. As patents expire in markets like China and India, around 30% of Novo's revenue from Wegovy and Ozempic may be impacted. Novo Nordisk anticipates a 5-13% sales decline this year due to competition and pricing pressures.
Feb 19, 2026
Biotechnology: streamlined, AI-focused, and prepared for the $400 billion patent expiration - Delano.lu
Lydia Haueter from Pictet Asset Management highlighted the biotechnology sector's pivotal role in drug development, driven by AI and innovative therapies. Biotech now leads in FDA drug approvals, with companies like Axsome Therapeutics, Abivax, and Mineralys emerging as key players. Despite policy concerns, the sector is poised for growth through M&A and a focus on unmet medical needs.
Feb 19, 2026
Following the expiration of its patent in March, the cost of the weight loss medication Semaglutide is expected to decrease by more than 65% in India, according to Ind-Ra.
Analysts at India Ratings and Research predict that the price of semaglutide, marketed as Ozempic and Wegovy, will drop over 65% to Rs 3,000-4,000 per month after its patent expires in March. This price reduction is expected due to increased competition from 7-10 new entrants in the market, despite the global growth of the GLP-1 segment.
Feb 19, 2026
Corcept Therapeutics Shares Drop Following Patent Case Appeal Loss - Bloomberg Law
Corcept Therapeutics' shares plummeted by 28%, reaching their lowest intraday level since 2024, following a ruling by the U.S. Court of Appeals for the Federal Circuit that Teva Pharmaceuticals did not infringe on its patents.
Feb 18, 2026
Dr. Reddy's plans to offer a Wegovy alternative at competitive prices, featuring discounts of 50-60%.
Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy at a price up to 60% lower than the branded product. The patent for semaglutide, the active ingredient in Wegovy, expires in March, allowing generics to enter the market. The company also aims to launch a biosimilar of cancer therapy Rituxan in the U.S.
Feb 18, 2026
Indian pharmaceutical company plans to offer Wegovy alternative at competitive prices, potentially up to a 60% discount.
Dr Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s weight-loss drug Wegovy, potentially priced 50-60% lower than the branded product. The patent for semaglutide expires in March, allowing entry into the Indian market. Additionally, Dr Reddy’s aims to introduce a biosimilar of cancer therapy rituximab, sold as Rituxan by Genentech and Biogen.
Feb 18, 2026
Could new weight-loss miracle pills have adverse effects on gut microbiota? - Retail Pharmacy
New research from the University of Adelaide raises concerns about salcaprozate sodium (SNAC), an absorption enhancer in oral semaglutide, used for obesity treatment. The study found that repeated SNAC exposure altered gut microbiota, increased inflammatory markers, and affected cognitive-related proteins in animal models. Researchers emphasize the need for further investigation into the long-term effects of SNAC as oral obesity treatments gain popularity.
Feb 18, 2026
Cellectar Biosciences obtains patents for a new cancer treatment | CLRB Stock Update
Cellectar Biosciences has expanded its global intellectual property estate, securing new patents across Europe, Asia-Pacific, and the Americas. This includes protection for its cancer-targeting drug conjugate, iopofosine I 131, ahead of a planned 3Q26 filing for conditional marketing approval with the EMA for Waldenström Macroglobulinemia. The company aims to enhance treatment options for cancer patients.
Feb 18, 2026
Top Selections: Microsoft, AbbVie, and PNC Showcase Dividend Increases in AI Sector
Don Nesbitt, portfolio manager at Emerald Advisers, highlighted Microsoft, AbbVie, and PNC Financial as top large-cap dividend stocks benefiting from AI advancements. He noted that while AbbVie faces challenges with Humira's exclusivity loss, its strong pipeline and AI's role in pharmaceuticals are promising. PNC is leveraging AI for efficiency, contributing to its dividend growth strategy.
Feb 18, 2026
Roche is looking for a purchaser for its highly successful antibiotic. - Bluewin
Roche is seeking a buyer for its antibiotic Rocephin, planning to end production in Kaiseraugst by the decade's end due to rising costs and generic competition. Despite this divestment, Roche continues to invest in new antibiotics research, emphasizing its commitment to the antibiotics sector. The decision follows extensive discussions with health authorities but no sustainable solution was reached.
Feb 18, 2026
Eli Lilly Enters Competition for Promising Inflammation Treatment, Acquiring CSL Drug Rights for $100 Million
Eli Lilly has acquired rights to CSL Limited's clinical-stage drug clazakizumab for $100 million, targeting chronic inflammation and cardiovascular disease. CSL retains rights for end-stage kidney disease prevention. Clazakizumab, an IL-6 blocking monoclonal antibody, aims to enhance medication adherence with long-acting injectables. Lilly's cardiometabolic pipeline includes drugs like lepodisiran and muvalaplin, reflecting its focus on expanding in this area.
Feb 18, 2026
Streamlining the Production of Weight-Loss Medications
Researchers, led by Dr. Fernando Albericio, are advocating for greener production methods for GLP-1 peptide agonists like Ozempic and Wegovy, traditionally synthesized through wasteful processes. At the upcoming Bioprocessing Summit Europe, Albericio will discuss the shift towards sustainable alternatives, emphasizing the importance of efficiency and ethical considerations in drug use for conditions like diabetes and obesity.
Feb 18, 2026
India's Pharmaceutical Industry at a Turning Point: Balancing Generic Strength with the Push for Innovation - Whalesbook
The Indian Patent Office's rejection of AbbVie Inc.'s Venetoclax patent allows immediate entry for generics, enhancing patient access and highlighting India's generics strength. However, it raises concerns about the need for Indian firms to innovate beyond generics to compete globally, especially against rising competitors like China. Future growth may depend on increased R&D investment and strategic partnerships.
Feb 18, 2026
NATCO Pharma Makes Significant Investments in New Medications and Acquisitions - Whalesbook
NATCO Pharma reported an 8.3% revenue increase to INR 705.4 Cr for Q3 FY26, with a net profit of INR 151.3 Cr. The company plans to launch Semaglutide and pursue major acquisitions, aiming for INR 10,000 Cr turnover in 5-10 years. However, litigation risks and declining sales from Revlimid pose challenges.
Feb 18, 2026
Will India always remain focused solely on generics? - Down To Earth
The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, allowing local companies to produce generics at significantly lower prices. This decision has sparked discussions about the future of India's pharmaceutical industry, questioning whether it will remain a generics producer or evolve into a hub for innovation amidst global advancements in biotechnology and drug development.
Feb 18, 2026
Authorities dismantle counterfeit hypertension medication operation; two distributors arrested, according to DrugsControl Media Services.
The Manpada police have dismantled a counterfeit medicine operation, arresting two distributors in Dombivli and Mumbai. The racket involved fake supplies of Telma AM, a commonly prescribed drug for hypertension.
Feb 18, 2026
Silo Pharma secures patent in Japan for PTSD medication SPC-15 - Stock Titan
Silo Pharma, Inc. has received a Notice of Allowance from the Japan Patent Office for its lead asset, SPC-15, a novel intranasal treatment for Post-Traumatic Stress Disorder (PTSD). This patent strengthens Silo's intellectual property portfolio and supports its strategy in global markets, according to CEO Eric Weisblum.
Feb 18, 2026
Initiator Pharma receives European patent for pudafensine targeting Female Sexual Dysfunction.
Initiator Pharma A/S has received a European patent for pudafensine, aimed at treating Female Sexual Dysfunction (FSD), including vulvodynia. The patent, granted by the European Patent Office, enhances the company's intellectual property portfolio and aligns with its ongoing Phase IIa study of pudafensine. This drug candidate, a triple monoamine reuptake inhibitor, shows promise in addressing significant unmet medical needs.
Feb 18, 2026
Legal challenges arise for AI drug discovery concerning patent and profit entitlements - DongA Science
As AI becomes integral to drug discovery, legal uncertainties over patent rights and profit sharing are intensifying. Experts highlight challenges in ownership, especially with AI-driven candidates like Insilico Medicine's 'Lentosertib' and Recursion's 'REC-994'. The 2022 'Thaler v. Vidal' ruling complicates matters, emphasizing the need for clear legal frameworks to expedite drug development and benefit patients.
Feb 18, 2026
STF Detains Three Individuals in Counterfeit Pharmaceutical Operation, Confiscates Large Quantity of Fake Medications
The Uttarakhand Special Task Force (STF) has arrested three individuals linked to a counterfeit medicine syndicate, seizing a large quantity of fake drugs imitating well-known brands. This operation marks a significant effort to combat the illegal pharmaceutical trade in the region.
Feb 18, 2026
Increasing Patents and Legal Actions Hinder Generic Rivals for Pharmaceutical Companies - BioSpace
A new analysis by Sean Tu from the University of Alabama highlights how brand-name pharmaceutical companies exploit the Hatch-Waxman Act to engage in serial litigation, delaying generic drug market entry and maintaining high prices. Companies like Sandoz face significant legal costs, with ongoing litigation over drugs like Allergan's Bimatoprost and Astellas' Myrbetriq, undermining competition and innovation.
Feb 18, 2026
Key Areas to Monitor in Pharma and Biotech Innovation and Competition by 2026 - Lexology
The FDA is undergoing significant changes, focusing on AI integration and clinical development efficiency under Commissioner Makary. Key issues include skinny labeling for generics, biosimilar interchangeability, patent listing practices, and the new Commissioner’s National Priority Voucher program. The Supreme Court is set to clarify induced infringement liability, impacting generic manufacturers. The FDA's AI initiatives aim to enhance product review processes.
Feb 18, 2026
Indian Pharmaceutical Company Plans to Introduce Generic Weight Loss Medication - National Today
Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight loss drug Wegovy, pending regulatory approval. The company aims to offer the generic semaglutide at a 60% discount to the branded product, potentially increasing access to obesity treatment for many patients. The announcement was made on February 17, 2026.
Feb 17, 2026
Transcript of Halozyme's (HALO) Earnings Call for Q4 2025 - The Globe and Mail
Halozyme Therapeutics reported a record total revenue of $1.4 billion for 2025, a 38% increase, driven by strong royalty streams from ENHANZE-enabled products like DARZALEX SC, Vyvgart Hytrulo, and Phesgo. The company anticipates continued growth, projecting 2026 revenue between $1.71 billion and $1.81 billion, while expanding its product pipeline through strategic acquisitions and collaborations.
Feb 17, 2026
India Strengthens Regulations on Pharmaceuticals, Nutritional Supplements, and Food Safety to Address ...
India is enhancing regulatory measures to address health risks from adulterated products, misuse of substances in sports, and environmental contaminants. Authorities are increasing inter-agency collaborations and enforcement actions to combat issues related to nutraceuticals, doping, and mislabeled nutritional supplements, as well as the misuse of prescription medicines.
Feb 17, 2026
BioNxt Achieves Key EPO Decision to Secure European Patent for Sublingual ... - BioSpace
BioNxt Solutions Inc. announced the European Patent Office has granted European Patent No. 4539857 for its sublingual cladribine oral thin film drug delivery technology. This patent, effective March 11, 2026, enhances BioNxt's intellectual property in Europe, supporting its commercialization strategy for BNT23001, aimed at treating multiple sclerosis and other autoimmune conditions.
Feb 17, 2026
Trump's Agreement with Argentina Represents a Significant Setback for Trade Favoring Big Pharma
The U.S.-Argentina trade agreement, signed under the Trump administration, mandates Argentina to adopt concessions from the Special 301 report, enhancing Big Pharma's monopoly power. Key provisions include repealing patenting guidelines, implementing data exclusivity, and extending patent terms, which threaten access to affordable medicines. Critics argue this deal undermines public interest in favor of corporate influence.
Feb 17, 2026
Dr. Reddy's plans to introduce a generic obesity medication with a 60% price reduction.
Dr Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s weight-loss drug Wegovy, potentially priced 50-60% lower than the branded product. The patent for semaglutide expires in March, allowing generics to enter the market. Additionally, Dr Reddy’s aims to launch a biosimilar of cancer therapy Rituxan in the U.S. pending approval.
Feb 17, 2026
Dr. Reddy's plans to introduce a generic obesity medication with a 60% price reduction - The HinduBusinessLine
Dr Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s weight-loss drug Wegovy at a price up to 60% lower than the branded product. The patent for semaglutide will expire in March, allowing generics to enter the market. The company also aims to launch a biosimilar of cancer therapy rituximab in the U.S. pending approval.
Feb 17, 2026
Cellectar Biosciences Broadens Its International Intellectual Property Assets in Preparation for Iopofosine I ...
Cellectar Biosciences, Inc. has expanded its global intellectual property portfolio, securing new patents for its cancer-targeting drug iopofosine I 131 and CLR 125 across Europe and other regions. This move supports the company's upcoming 3Q26 filing for conditional marketing approval with the EMA for iopofosine I 131 as a treatment for Waldenström macroglobulinemia.
Feb 17, 2026
Dr. Reddy's plans to introduce a generic obesity medication with a 60% price reduction - News India Times
Dr. Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight loss drug Wegovy, pending approval, at a price approximately 60% lower than the branded version. The company recently received approval to manufacture and sell a generic version of the diabetes drug Ozempic and is awaiting approval for Wegovy.
Feb 17, 2026
Dr. Reddy's Aims at GLP-1 Leaders with 60% More Affordable Generic Option - Whalesbook
Dr. Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy at about 60% less than the branded price, following approval for a generic Ozempic. This move aims to disrupt the GLP-1 market, projected to reach $132 billion by 2035, but faces regulatory hurdles and potential pushback from Novo Nordisk.
Feb 17, 2026
Eli Lilly Shifts Focus to Establish India as a Global Pharmaceutical Supply Center - Whalesbook
Eli Lilly is investing over $1 billion to transform India into a key global manufacturing hub, driven by the success of its obesity drug Mounjaro. This strategic move aims to enhance supply chain resilience and challenge competitors like Novo Nordisk. Lilly's dual-action therapies, including Mounjaro and Zepbound, show superior efficacy, positioning the company for growth in the expanding obesity treatment market.
Feb 17, 2026
AbbVie's Stock Declines Following Q4 Earnings Release: Investment Strategies to Consider - The Globe and Mail
AbbVie (ABBV) reported better-than-expected Q4 results but saw its stock decline due to falling oncology sales and challenges in its aesthetics segment. Despite losing patent protection for Humira, AbbVie’s new drugs, Skyrizi and Rinvoq, generated $26 billion in 2025 and are expected to drive growth. The company anticipates a 9.5% revenue increase in 2026, supported by strong sales in neuroscience and ongoing acquisitions.
Feb 17, 2026
Dr. Reddy's intends to introduce a generic obesity medication with a significant price reduction of 60% | Health News
Dr Reddy's Laboratories plans to launch a generic version of Novo Nordisk's weight-loss drug Wegovy at a price up to 60% lower than the branded product. The patent for semaglutide, the active ingredient in Wegovy, expires in March, allowing generics to enter the market. The company also aims to launch a biosimilar of cancer therapy rituximab in the U.S.
Feb 17, 2026
Will BMY's Growth Portfolio Offset the Decline of Legacy Medications by 2026? - Finviz
Bristol Myers Squibb (BMY) reported flat revenues for 2025, with a 17% increase in its growth portfolio, including Opdivo and Reblozyl, offsetting a 15% decline in legacy products like Revlimid and Pomalyst due to generic competition. The company anticipates a further 12-16% decline in legacy sales for 2026, while facing competition from Merck's Keytruda and Cytokinetics' Myqorzo.
Feb 17, 2026
Dr. Reddy's announces that its version of Wegovy will be offered at competitive prices, potentially featuring discounts of 50-60%.
Dr Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s weight-loss drug Wegovy, potentially priced 50-60% lower than the branded product. The patent for semaglutide expires in March, allowing generics to enter the market. Additionally, Dr Reddy’s aims to launch a biosimilar of cancer therapy rituximab in the U.S. pending regulatory approval.
Feb 17, 2026
Eli Lilly targets India to become a key global manufacturing center in response to increasing drug demand | Health News
Eli Lilly, the maker of Mounjaro, aims to establish India as a global supply chain hub, backed by a $1 billion investment in contract manufacturing. Following the rapid success of Mounjaro in India, which became the top-selling weight-loss drug, the company plans to export locally produced medications worldwide, leveraging India's strong manufacturing capabilities.
Feb 17, 2026
Ocular Therapeutix Plans FDA Submission Following Phase 3 Trial Success of Wet AMD Treatment Over Regeneron's Eylea
Ocular Therapeutix's drug Axpaxli, developed for wet age-related macular degeneration, outperformed Regeneron Pharmaceuticals' Eylea in maintaining vision for patients, with 74.1% of Axpaxli patients retaining vision at week 36 compared to 55.8% for Eylea. Ocular plans to discuss FDA submission based on these Phase 3 results, which also suggest less frequent dosing.
Feb 17, 2026
Weight-loss miracle pills face examination over their main component - Medical Xpress
A study from Adelaide University published in the Journal of Controlled Release raises concerns about salcaprozate sodium (SNAC), an ingredient in oral semaglutide, a weight-loss drug. The research indicates potential adverse effects on gut health and inflammation, highlighting the need for further investigation as the use of oral obesity treatments increases globally.
Feb 17, 2026
Delaware considers reducing GLP-1 coverage in state insurance plan - InsuranceNewsNet
Delaware's state spending on blockbuster weight-loss drugs is rising sharply, potentially leading to increased out-of-pocket costs for employees covered under the state's health plan. This change may result in some employees being uncovered for their weight-loss prescriptions.
Feb 16, 2026
Study: FDA medication labels do not confirm patent infringement - Medical Xpress
A new paper co-authored by Jacob S. Sherkow from the University of Illinois argues that recent court decisions treating FDA-required drug labels as key evidence in patent infringement cases against generic-drug manufacturers are flawed. The U.S. Supreme Court is urged to reverse this trend in the upcoming case Hikma Pharmaceuticals U.S. v. Amarin Pharma, to protect access to affordable medications.
Feb 16, 2026
Novo Nordisk's Patent Dispute with Hims and Hers Highlights Valuation Concerns - Yahoo Finance
Novo Nordisk has filed a lawsuit against Hims & Hers Health for allegedly infringing patents related to its obesity drugs. The case highlights the challenges branded drugmakers face from low-cost copycat medications. As Novo Nordisk's stock (CPSE:NOVO B) declines, the lawsuit's outcome may impact pricing and regulation of obesity treatments in the U.S.
Feb 16, 2026
Episode 452: 10:1 Risk/Reward: Three Pharmaceutical Monopolies Designed for Significant Gains
In the latest Stansberry Investor Hour, Dave Lashmet discusses three biopharmaceutical companies monopolizing weight-loss drugs. He highlights a company targeting obesity and Type 2 diabetes, another focusing on fatty liver disease, and a third using genetics for appetite suppression. Lashmet emphasizes the potential of these drugs, particularly a once-a-day pill for fatty liver disease, projected to become a $2 billion market by 2026.
Feb 16, 2026
AstraZeneca's court victory puts a stop to a more affordable diabetes medication - Yahoo News Australia
AstraZeneca has successfully blocked Sydney-based Pharmacor from listing generic versions of its diabetes drug Forxiga, which contains dapagliflozin, on Australia's Pharmaceutical Benefits Scheme. The court ruled that allowing Pharmacor to sell its products would irreparably harm AstraZeneca's patent rights. The trial is set to begin in August, as Pharmacor claims the patent is invalid.
Feb 16, 2026
AstraZeneca's court victory puts a stop to a lower-cost diabetes medication - AAP News
AstraZeneca has successfully blocked Sydney-based Pharmacor from listing generic versions of its diabetes drug Forxiga, which contains dapagliflozin, on Australia's Pharmaceutical Benefits Scheme. The Federal Court ruled in favor of AstraZeneca, citing patent infringement, and granted an injunction against Pharmacor. The trial is set to begin in August, as AstraZeneca aims to protect its market monopoly until the patent expires in 2027.
Feb 16, 2026
AstraZeneca's legal victory puts a stop to a more affordable diabetes medication - | National News
AstraZeneca's Forxiga, containing dapagliflozin, generated $8.5 billion in revenue in 2025 and is crucial for its growth in Australia. The company successfully blocked Sydney-based Pharmacor from listing generic versions on the Pharmaceutical Benefits Scheme due to patent infringement. A trial is set for August, as Pharmacor claims the patent is invalid but acknowledges infringement.
Feb 16, 2026
Eli Lilly Utilizes Artificial Intelligence to Revolutionize Pharmaceutical Development | Intellectia.AI
Wall Street analysts have upgraded Eli Lilly (LLY) stock, forecasting a price increase to $1,200 from $1,050, citing strong Q4 results and record GLP-1 sales. BMO Capital also raised its target to $1,300, emphasizing Lilly's leadership in the incretin market. Analysts maintain a positive outlook on the company's growth potential through 2026.
Feb 16, 2026
Novo Nordisk Adjusts Approach Amid Growing Competition in US Weight-Loss Medication Pricing
Novo Nordisk plans to launch a lower-cost vial version of its weight-loss drug Wegovy in response to Eli Lilly's aggressive pricing strategies with Zepbound. CEO Mike Doustdar highlighted the need for competitive pricing amid market challenges. The company is also pursuing legal action against Hims & Hers for unauthorized Wegovy copies. Despite a revenue increase, forecasts for 2026 are cautious, predicting declines.
Feb 16, 2026
FDA-mandated medication labels should not be considered proof of patent violation.
A new paper co-authored by Jacob S. Sherkow from the University of Illinois argues that recent court decisions treating FDA-required drug labels as key evidence in patent cases against generic-drug manufacturers are flawed. The Supreme Court is set to hear Hikma Pharmaceuticals USA v. Amarin Pharma, which could clarify that labeling language alone does not constitute patent infringement, potentially improving access to affordable generics.
Feb 15, 2026
China's biotechnology sector is experiencing rapid growth, with over $1 billion in investments occurring weekly.
Biwon, a Chinese biotech company, has surpassed Hang Li Pharmaceutical in sales, driven by the success of its blood cancer treatment, Brukinsa, which generated over $4 billion in 2025. Brukinsa's FDA approval and superior efficacy compared to Imbruvica have established it as a leading treatment in the U.S. market, showcasing China's growing biotech competitiveness.
Feb 15, 2026
Individuals claim that the 'terrible' side effects of GLP-1 are 'justifiable' for the sake of losing weight.
A study from Rutgers University and the University of Sydney reveals that users of Ozempic, a GLP-1 medication, are willing to endure severe gastrointestinal side effects like nausea and vomiting for weight loss. Despite adverse reactions, two-thirds of users reported satisfaction with their weight loss results, indicating a strong commitment to the drug despite its challenges.
Feb 15, 2026
Numerous individuals taken into custody as authorities confiscate crores of diverted codeine syrup in multiple states.
Law enforcement agencies in India have arrested dozens and seized crores worth of diverted codeine-based cough syrups and alprazolam tablets in a crackdown on narcotic rackets. The operations come amid rising concerns over the misuse of prescription drugs for intoxication.
Feb 15, 2026
Delhi Police Takes Action Against Illegal Pharmaceutical Drug Operation: Two Individuals Arrested in Significant Bust of ...
Delhi Police's Anti-Narcotics Task Force has arrested two individuals in West Delhi, dismantling an illegal drug supply network. The operation led to a significant seizure of Tramadol capsules and Codeine-based cough syrup, violating the NDPS Act. The crackdown targets the illicit diversion of pharmaceutical drugs, highlighting ongoing efforts to combat drug-related crimes.
Feb 15, 2026
High Court Rejects Bail in Major Psychotropic Drug Seizure Case, References Strict Provisions of NDPS Act
The Punjab and Haryana High Court has denied bail to eight individuals involved in a major psychotropic drug seizure case, emphasizing the strict enforcement of the NDPS Act. The court warned against using licenses as a shield in drug trafficking activities, highlighting the organized nature of the alleged network.
